Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis

Yen Chien Lee, Chung Cheng Hsieh, Yen Ling Lee, Chung Yi Li

研究成果: Review article同行評審

1 引文 斯高帕斯(Scopus)

摘要

Molecular markers are important in guiding treatment and predicting outcome in the genomic era. Meta-analysis of molecular markers in myelofibrosis through a search of PubMed and Medline through October 31, 2017 was performed. Markers with more than 3 studies that compared overall survival (OS) and leukemia-free survival (LFS) were analyzed. A total of 16 studies were included. Hazard ratios (HRs) for OS were as follows: IDH 2.65 (95% confidence interval [CI], 1.66-4.21), SRSF2 2.12 (95% CI, 1.18-3.79), high-risk myeloma 2.11 (95% CI, 1.70-2.61), ASXL1 1.92 (95% CI, 1.60-2.32), EZH2 1.88 (95% CI, 1.32-2.67), JAK2 1.41 (95% CI, 1.04-1.93) in the univariate analysis and 1.49 (95% CI, 0.42-5.30) in the multivariate analysis. LFS of JAK2 and SRSF2 had HRs of 1.81 (95% CI, 0.42-5.30) and 0.36 (95% CI, 0.02-6.48), respectively. In conclusion, mutations in IDH, SRSF2, and ASXL1 had worse prognosis in OS with HRs around 2. JAK2 and SRSF2 mutation were not associated with increased leukemia transformation. The adverse effect of triple-negative, which was often compared with CALR mutation, needs to be explored.

原文English
頁(從 - 到)558-568
頁數11
期刊Clinical Lymphoma, Myeloma and Leukemia
18
發行號9
DOIs
出版狀態Published - 2018 九月

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

指紋 深入研究「Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis」主題。共同形成了獨特的指紋。

引用此